DeepMed Research

insulin

Generic Name: insulin

Clinical Trials

Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.

Phase 4

Conditions: Acute Pancreatitis
Hypertriglyceridemia

Interventions: Device: plasmapheresis
Drug: Insulin

First Posted Date: 2018-04-18

Last Posted Date: 2018-06-06

Lead Sponsor: First Affiliated Hospital of Wenzhou Medical University

Target Recruit Count: 200

Registration Number: NCT03501680

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed

Conditions: Diabetes Mellitus, Type 2
Cardiovascular Diseases

Interventions: Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Drug: Empagliflozin
Drug: Canagliflozin
Drug: Dapagliflozin
Drug: Glucagon-like Peptide-1 (GLP-1) Agonist
Drug: Anti-hyperglycemic Agents (AHA)
Drug: Thiazolidinediones (TZD)
Drug: Sulfonylureas (SU)
Drug: Insulin

First Posted Date: 2018-04-10

Last Posted Date: 2018-08-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 714582

Registration Number: NCT03492580

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose

Early Phase 1

Completed

Conditions: Hyperglycaemia (Diabetic)

Interventions: Drug: Insulin
Behavioral: exercise
Dietary Supplement: Dietary counseling

First Posted Date: 2018-03-19

Last Posted Date: 2024-02-05

Lead Sponsor: Yale University

Target Recruit Count: 8

Registration Number: NCT03469492

Locations: 🇺🇸
The Anylan Center, New Haven, Connecticut, United States

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin
Drug: Insulin
Drug: Placebo
Drug: Linagliptin
Drug: Empagliflozin

First Posted Date: 2018-02-12

Last Posted Date: 2024-02-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 175

Registration Number: NCT03429543

Locations: 🇺🇸
Children's Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸
Atlanta Center, Atlanta, Georgia, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 79 locations

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Phase 3

Terminated

Conditions: Obesity
Diabetes Mellitus, Type 2

Interventions: Drug: Dapagliflozin 10mg
Drug: Placebo Oral Tablet
Drug: Exenatide 2 mg [Bydureon]
Drug: Placebo injection
Drug: Insulin
Drug: Metformin, if taken before

First Posted Date: 2018-02-05

Last Posted Date: 2020-03-31

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 13

Registration Number: NCT03419624

Locations: 🇩🇪
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
🇩🇪
Diabeteszentrum Oldenburg, Oldenburg, Lower Saxony, Germany
🇩🇪
Diabetologische Schwerpunktpraxis Harburg, Hamburg, Germany

and more 1 locations

ُEfficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients

Not Applicable

Conditions: Treatment Resistant Carpal Tunnel in RA Patients

Interventions: Other: saline
Drug: Hylase
Drug: Insulin

First Posted Date: 2018-01-09

Last Posted Date: 2018-07-13

Lead Sponsor: Assiut University

Target Recruit Count: 90

Registration Number: NCT03394131

Locations: 🇪🇬
Manal Hassanien, Assiut, Assuit, Egypt

Insulin-based Strategies to Prevent Hypoglycemia During Exercise

Not Applicable

Conditions: Type 1 Diabetes Mellitus

Interventions: Other: Exercise 1
Other: Exercise 2
Device: Dexcom G4 Platinum
Drug: Insulin
Device: Insulin pump

First Posted Date: 2017-11-21

Last Posted Date: 2018-05-22

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 20

Registration Number: NCT03349489

Locations: 🇨🇦
McGill University Health Centre, Montreal, Quebec, Canada
🇨🇦
Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada

Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis

Phase 4

Conditions: Pancreatitis, Acute
Hypertriglyceridemia

Interventions: Drug: Insulin
Device: Aphesis

First Posted Date: 2017-11-17

Last Posted Date: 2017-11-17

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 220

Registration Number: NCT03342807

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Phase 2

Completed

Conditions: Hyperkalemia

Interventions: Drug: Sodium Zirconium Cyclosilicate(ZS)
Drug: Placebo
Drug: Insulin
Drug: Glucose

First Posted Date: 2017-11-09

Last Posted Date: 2020-01-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 70

Registration Number: NCT03337477

Locations: 🇷🇺
Research Site, Yekaterinburg, Russian Federation

Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus

Phase 3

Completed

Conditions: Gestational Diabetes Mellitus in Pregnancy

Interventions: Drug: Insulin
Drug: Metformin

First Posted Date: 2017-10-25

Last Posted Date: 2017-10-27

Lead Sponsor: Services Institute of Medical Sciences, Pakistan

Target Recruit Count: 278

Registration Number: NCT03320694

Locations: 🇵🇰
Services Institute of Medical Sciences, Lahore, Punjab, Pakistan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy